18.20
-0.56(-2.99%)
Currency In USD
Address
116 Huntington Avenue
Boston, MA 02116
United States of America
Phone
617-468-4219
Website
Sector
Healthcare
Industry
Biotechnology
Employees
55
First IPO Date
September 13, 2024
| Name | Title | Pay | Year Born |
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | Chief Executive Officer & Director | 829,800 | 1989 |
| Mr. Ryan Cohlhepp Pharm.D. | President, Chief Operating Officer & Director | 825,750 | 1977 |
| Mr. Ivan Hyep M.B.A. | Chief Financial Officer | 915,375 | 1985 |
| Ms. Pauline Dufresne | Chief People Officer | 0 | N/A |
| Ms. Rachel Salazar | SVice President of R&D Strategy and Operations | 0 | N/A |
| Ms. Sathish Hasige Ph.D. | Senior Vice President and Head of Technical Operations & Supply Chain | 0 | N/A |
| Dr. David Raben M.D. | Chief Medical Officer | 0 | 1963 |
| Ms. Angela Windt | Vice President & Head of Regulatory Affairs | 0 | N/A |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs | 0 | N/A |
| Ms. Lara S. Meisner J.D. | Chief Legal Officer & Corporate Secretary | 0 | 1973 |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
